A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the comparative efficacy and safety of three different
doses ( 110 mg, 150 mg, 220 mg) of BIBR 1048 (Dabigatran etexilate) orally, compared to
placebo, in prevention of venous thromboembolism in patient with primary elective total knee
replacement surgery, and to evaluate dose-response.